Oligonucleotide Therapeutics: Case Studies, Current Industry Recommendations, & Future Perspectives

Time: 4:00 pm
day: Conference Day One

Details:

  • Detection and risk assessment of hybridization-mediated off-targets
  • Current strategic recommendations from an industrial perspective
  • Pending challenges and the need for enhanced specificity and selectivity’

Speakers: